section name header

Pronunciation

PROE-poe-fol

Classifications

Therapeutic Classification: general anesthetics

Indications

High Alert


Action

  • Short-acting hypnotic. Mechanism of action is unknown.
  • Produces amnesia.
  • Has no analgesic properties.
Therapeutic effects:
  • Induction and maintenance of anesthesia.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Rapidly and widely distributed. Crosses the blood-brain barrier well; rapidly redistributed to other tissues.

Protein Binding: 95–99%.

Metabolism/Excretion: Rapidly metabolized by the liver. Primarily excreted in urine as metabolites.

Half-Life: 3–12 hr (blood-brain equilibration half-life 2.9 min).

Time/Action Profile

(loss of consciousness)

ROUTEONSETPEAKDURATION
IV40 secunknown3–5 min



Time to recovery is 8 min (up to 19 min if opioid analgesics have been used).



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: bradycardia, hypotension, hypertension

Derm: flushing

GI: abdominal cramping, hiccups, nausea, vomiting

GU: discoloration of urine (green)

Local: burning, pain, stinging, coldness, numbness, tingling at IV site

MS: involuntary muscle movements, perioperative myoclonia

Neuro: dizziness, headache

Resp: apnea, cough

Misc: fever, PROPOFOL INFUSION SYNDROME

Interactions

Drug-drug:

Route/Dosage

General Anesthesia

Monitored Anesthesia Care Sedation

ICU Sedation

Availability

(Generic available)

Assessment

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Diprivan